30.06.2013 Views

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

claimants (and unsuccessful drug company tenderers) could not know under<br />

which criteria <strong>the</strong>ir applications were or were not successful.<br />

One contributor to <strong>the</strong> literature (Seddon, 1999) and a past or present Health<br />

Minister interviewee, pointed out that simply being explicit and open about<br />

decisions will not necessarily satisfy people that <strong>the</strong> right decisions were made.<br />

The media study identified Community <strong>Exceptional</strong> Circumstances claimants<br />

who were refused access to medication, who rightly or wrongly believed <strong>the</strong>ir<br />

lives were being unnecessarily shortened by PHARMAC’s decisions. The main<br />

reason for <strong>the</strong>ir complaint was that <strong>the</strong>y did not really know why <strong>the</strong>se micro-<br />

level rationing decisions were made.<br />

This same complaint was also made by drug companies and <strong>the</strong>ir<br />

representative body Medicines New Zealand, who sought to have new drugs<br />

listed by PHARMAC for subsidy. PHARMAC’s approach to openness was also<br />

discussed by <strong>the</strong> NZORD. They stated that <strong>the</strong> PHARMAC’s panel members<br />

do not listen to NZORD clinical experts or evidence <strong>of</strong> experience in treatment<br />

regimes from o<strong>the</strong>r jurisdictions. This lobby group complained that PHARMAC<br />

unreasonably delayed decisions and made unnecessary requests for<br />

information when <strong>the</strong> same medicines were accepted and listed in o<strong>the</strong>r<br />

comparable countries, for example Australia.<br />

Curiously, evidence was presented in <strong>the</strong> key informant interviews and in <strong>the</strong><br />

media stories that pharmaceutical companies sometimes encourage patients<br />

and <strong>the</strong>ir doctors to make Community <strong>Exceptional</strong> Circumstances claims about<br />

medicines that are available in Australia. This begins PHARMAC’s assessment<br />

process and is a way <strong>of</strong> medicines becoming discussed in <strong>the</strong> media. This is an<br />

example <strong>of</strong> manufacturing companies not being open about <strong>the</strong>ir motives or <strong>the</strong><br />

financial implications <strong>of</strong> <strong>the</strong>ir gaining favourable decisions.<br />

In Daniels and Sabin’s (2008) ‘Accountability for Reasonableness’ framework,<br />

<strong>the</strong>y described <strong>the</strong> need for openness as an important element <strong>of</strong> a fair<br />

process. This element referred to <strong>the</strong> need to be public about <strong>the</strong> reasons and<br />

225

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!